To The Editor,

We read the article [@b0005] "Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19" by Tchelebi et al. with great interest. We commend the authors for providing guidance on various gastrointestinal malignancies during the COVID-19 pandemic. Notably, with regard to the treatment of locally advanced anal cancer, the authors recommend definitive chemoradiation (CRT). The concurrent chemotherapy regimen recommended per the authors is mitomycin-C (MMC) plus capecitabine or fluorouracil (5FU), and that changes to this chemotherapy are not indicated during the global pandemic.

MMC is known to increase the risk of neutropenia and leukopenia, and thus increase the risk of infection. It is critical to be mindful in particular of the hematologic toxicity (HT) of CRT, and therefore, we suggest that there should be careful consideration of the concurrent chemotherapy regimen used in locally advanced anal cancer in the era of COVID-19, a time during which avoiding HT is paramount. RTOG-9811 [@b0010], [@b0015], which randomized patients to radiation (RT) + 5FU/MMC versus induction 5-FU/cisplatin (CDDP) followed by RT + 5FU/CDDP demonstrated significantly improved disease free survival (DFS) and overall survival (OS) and a trend towards improved colostomy-free survival (CFS) in the MMC arm. Yet, a crucial caveat of this trial was the use of induction chemotherapy in the CDDP-based arm, which delayed local therapy and potentially leading to more favorable disease-related outcomes in the MMC-based arm. Nevertheless, there was significantly higher grade 3--4 acute HT (62% vs 42%) in patients treated with MMC versus CDDP. The rate of grade 3--4 acute HT was also found to be lower and ranged from 12% to 19% in the CDDP-based regimens of UNICANCER ACCORD-03 [@b0020]. In a 2×2-factorial superiority-design phase III trial, the UKCCR ACT II [@b0025] study randomized patients to MMC-based CRT versus CDDP-based CRT followed by CDDP-based maintenance chemotherapy versus no maintenance. In ACT II, the largest anal cancer trial to date, disease-related outcomes of DFS, OS, and CFS were not significantly different between the CDDP and MMC-based arms. Yet, acute HT (grade 3--4, 26% vs 16%) was higher in the MMC arm. Despite CDDP-based regimens having comparable outcomes as shown in ACT II with less acute HT, MMC-based regimens continue to be more commonly used in locally advanced anal cancer.

Even in the pre-COVID-19 era, our institutional practice has always favored using the doublet of CDDP/5FU weekly in an effort to reduce acute HT in all patients with anal cancer, but particularly among immunocompromised (such as those with human immunodeficiency virus \[HIV\] infection) and older patients, both of whom are prone to anal cancer. Notably, earlier anal cancer trials excluded those with HIV infection, who are not only at increased risk for anal cancer but are also more susceptible to HT from CRT. At our institution, we administer CDDP (20 mg/m^2^ weekly) with 5FU (300 mg/m^2^/day on days of radiation). In our published experience [@b0030] of 197 patients with locally advanced anal cancer treated with concurrent CDDP/5FU and RT, there was only one patient that developed grade 3 neutropenia. Moreover, grade 4 myelosuppression was not observed. Weekly administration of CDDP/5FU in our retrospective analysis resulted in a more favorable HT profile for this patient population than prior prospective experiences with CDDP/5FU (such as ACT II), which were administered on weeks 1 and 5. This CDDP-based regimen was not only well-tolerated, but was also just as clinically effective (5‐year DFS 81%, 5‐year OS 86%, and 5‐year CFS 88%).

Together, we submit that the doublet of CDDP/5FU should be strongly considered as part of concurrent CRT in the treatment of locally advanced anal cancer during the pandemic, when avoiding HT in patients who are already at risk for severe infection from COVID-19 is of utmost importance.
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